New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor

Rosemeire Takeuchi, Luca Szalontay, Andrew V Schally, Lauro M. Takeuchi, Petra Popovics, Miklos Jaszberenyi, Irving Vidaurre, Marta Zarandi, Ren Zhi Cai, Norman L Block, Joshua Hare, Ferenc G. Rick

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: We previously showed that growth hormone-releasing hormone (GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH agonists, and elucidate their mechanisms of action in promoting cardiac repair. Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking nutritional deprivation. GHRH agonists decreased calcium influx and significantly improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356, MR-409); this accompanied an increased number of cardiac c-kit<sup>+</sup> cells, cellular mitotic divisions, and vascular density. One week post-MI, MR-409 significantly reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene expression studies revealed favorable outcomes of MR-409 treatment partially result from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by elevation of bone morphogenetic proteins. Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.

Original languageEnglish (US)
Pages (from-to)9728-9739
Number of pages12
JournalOncotarget
Volume6
Issue number12
StatePublished - 2015

Fingerprint

Growth Hormone-Releasing Hormone
Heart Failure
Myocardial Infarction
Therapeutics
Placebos
Bone Morphogenetic Proteins
Serum-Free Culture Media
somatotropin releasing hormone receptor
Interleukin-10
Infarction
Interleukin-2
Blood Vessels
Cultured Cells
Interleukin-6
Cell Survival
Fibrosis
Apoptosis
Calcium
Gene Expression

Keywords

  • Cardioprotection
  • Growth hormone-releasing hormone
  • Heart failure
  • Myocardial infarction
  • Remodeling

ASJC Scopus subject areas

  • Oncology

Cite this

New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. / Takeuchi, Rosemeire; Szalontay, Luca; Schally, Andrew V; Takeuchi, Lauro M.; Popovics, Petra; Jaszberenyi, Miklos; Vidaurre, Irving; Zarandi, Marta; Cai, Ren Zhi; Block, Norman L; Hare, Joshua; Rick, Ferenc G.

In: Oncotarget, Vol. 6, No. 12, 2015, p. 9728-9739.

Research output: Contribution to journalArticle

Takeuchi, R, Szalontay, L, Schally, AV, Takeuchi, LM, Popovics, P, Jaszberenyi, M, Vidaurre, I, Zarandi, M, Cai, RZ, Block, NL, Hare, J & Rick, FG 2015, 'New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor', Oncotarget, vol. 6, no. 12, pp. 9728-9739.
Takeuchi, Rosemeire ; Szalontay, Luca ; Schally, Andrew V ; Takeuchi, Lauro M. ; Popovics, Petra ; Jaszberenyi, Miklos ; Vidaurre, Irving ; Zarandi, Marta ; Cai, Ren Zhi ; Block, Norman L ; Hare, Joshua ; Rick, Ferenc G. / New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. In: Oncotarget. 2015 ; Vol. 6, No. 12. pp. 9728-9739.
@article{1c96d19e0c3a4077a5db4136e941abea,
title = "New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor",
abstract = "Background: We previously showed that growth hormone-releasing hormone (GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH agonists, and elucidate their mechanisms of action in promoting cardiac repair. Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking nutritional deprivation. GHRH agonists decreased calcium influx and significantly improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356, MR-409); this accompanied an increased number of cardiac c-kit+ cells, cellular mitotic divisions, and vascular density. One week post-MI, MR-409 significantly reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene expression studies revealed favorable outcomes of MR-409 treatment partially result from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by elevation of bone morphogenetic proteins. Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.",
keywords = "Cardioprotection, Growth hormone-releasing hormone, Heart failure, Myocardial infarction, Remodeling",
author = "Rosemeire Takeuchi and Luca Szalontay and Schally, {Andrew V} and Takeuchi, {Lauro M.} and Petra Popovics and Miklos Jaszberenyi and Irving Vidaurre and Marta Zarandi and Cai, {Ren Zhi} and Block, {Norman L} and Joshua Hare and Rick, {Ferenc G.}",
year = "2015",
language = "English (US)",
volume = "6",
pages = "9728--9739",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor

AU - Takeuchi, Rosemeire

AU - Szalontay, Luca

AU - Schally, Andrew V

AU - Takeuchi, Lauro M.

AU - Popovics, Petra

AU - Jaszberenyi, Miklos

AU - Vidaurre, Irving

AU - Zarandi, Marta

AU - Cai, Ren Zhi

AU - Block, Norman L

AU - Hare, Joshua

AU - Rick, Ferenc G.

PY - 2015

Y1 - 2015

N2 - Background: We previously showed that growth hormone-releasing hormone (GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH agonists, and elucidate their mechanisms of action in promoting cardiac repair. Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking nutritional deprivation. GHRH agonists decreased calcium influx and significantly improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356, MR-409); this accompanied an increased number of cardiac c-kit+ cells, cellular mitotic divisions, and vascular density. One week post-MI, MR-409 significantly reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene expression studies revealed favorable outcomes of MR-409 treatment partially result from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by elevation of bone morphogenetic proteins. Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.

AB - Background: We previously showed that growth hormone-releasing hormone (GHRH) agonists are cardioprotective following myocardial infarction (MI). Here, our aim was to evaluate the in vitro and in vivo activities of highly potent new GHRH agonists, and elucidate their mechanisms of action in promoting cardiac repair. Methods and Results: H9c2 cells were cultured in serum-free medium, mimicking nutritional deprivation. GHRH agonists decreased calcium influx and significantly improved cell survival. Rats with cardiac infarction were treated with GHRH agonists or placebo for four weeks. MI size was reduced by selected GHRH agonists (JI-38, MR-356, MR-409); this accompanied an increased number of cardiac c-kit+ cells, cellular mitotic divisions, and vascular density. One week post-MI, MR-409 significantly reduced plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo. Gene expression studies revealed favorable outcomes of MR-409 treatment partially result from inhibitory activity on pro-apoptotic molecules and pro-fibrotic systems, and by elevation of bone morphogenetic proteins. Conclusions: Treatment with GHRH agonists appears to reduce the inflammatory responses post-MI and may consequently improve mechanisms of healing and cardiac remodeling by regulating pathways involved in fibrosis, apoptosis and cardiac repair. Patients with cardiac dysfunction could benefit from treatment with novel GHRH agonists.

KW - Cardioprotection

KW - Growth hormone-releasing hormone

KW - Heart failure

KW - Myocardial infarction

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=84929589859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929589859&partnerID=8YFLogxK

M3 - Article

C2 - 25797248

AN - SCOPUS:84929589859

VL - 6

SP - 9728

EP - 9739

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -